Literature DB >> 26602549

Immunotherapy in Peripheral Neuropathies.

Jean-Marc Léger1, Raquel Guimarães-Costa2, Cristina Muntean2.   

Abstract

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

Entities:  

Keywords:  Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barré syndrome; IgM anti-myelin-associated-glycoprotein neuropathy; Immune-mediated neuropathies; Immunomodulatory treatments; Multifocal motor neuropathy

Mesh:

Substances:

Year:  2016        PMID: 26602549      PMCID: PMC4720673          DOI: 10.1007/s13311-015-0401-7

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  100 in total

Review 1.  Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition.

Authors:  Jean-Michel Vallat; Claudia Sommer; Laurent Magy
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 2.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael P T Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  The discovery of the Guillain-Barré syndrome and related disorders.

Authors:  Richard Hughes; Jean-Marc Léger
Journal:  Presse Med       Date:  2013-04-28       Impact factor: 1.228

4.  Interferon beta-1a as an investigational treatment for CIDP.

Authors:  J-M Vallat; A F Hahn; J-M Léger; D P Cros; L Magy; F Tabaraud; P Bouche; P-M Preux
Journal:  Neurology       Date:  2003-04-01       Impact factor: 9.910

5.  Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.

Authors:  Filip Eftimov; Marinus Vermeulen; Rob J de Haan; Leonard H van den Berg; Ivo N van Schaik
Journal:  J Peripher Nerv Syst       Date:  2009-06       Impact factor: 3.494

6.  Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.

Authors:  R M Van den Berg-Vos; H Franssen; J H J Wokke; L H Van den Berg
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

7.  Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.

Authors: 
Journal:  Lancet Neurol       Date:  2009-01-10       Impact factor: 44.182

8.  Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.

Authors:  Sanne Piepers; Renske Van den Berg-Vos; W-Ludo Van der Pol; Hessel Franssen; John Wokke; Leonard Van den Berg
Journal:  Brain       Date:  2007-07-10       Impact factor: 13.501

Review 9.  Intravenous immunoglobulin for multifocal motor neuropathy.

Authors:  I N van Schaik; L H van den Berg; R de Haan; M Vermeulen
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

10.  Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Authors:  Jean-Marc Léger; Jan L De Bleecker; Claudia Sommer; Wim Robberecht; Mika Saarela; Jerzy Kamienowski; Zbigniew Stelmasiak; Orell Mielke; Björn Tackenberg; Amgad Shebl; Artur Bauhofer; Othmar Zenker; Ingemar S J Merkies
Journal:  J Peripher Nerv Syst       Date:  2013-06       Impact factor: 3.494

View more
  7 in total

Review 1.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 2.  Sleep Disturbances Associated with Neurological Autoimmunity.

Authors:  Michelle F Devine; Erik K St Louis
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

3.  Report on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy - September 24-26, 2015, Ottawa, Canada.

Authors:  Jodi Warman Chardon; Bernard J Jasmin; Rashmi Kothary; Robin J Parks
Journal:  J Neuromuscul Dis       Date:  2016-08-30

Review 4.  Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2018-01-15       Impact factor: 6.570

Review 5.  Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.

Authors:  Luis Querol; Cinta Lleixà
Journal:  Neurotherapeutics       Date:  2021-09-21       Impact factor: 7.620

6.  IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig®-The LIME Study.

Authors:  Jean-Marc Léger; Ousmane Alfa Cissé; Dario Cocito; Jean-Marie Grouin; Haider Katifi; Eduardo Nobile-Orazio; Rabye Ouaja; Jean Pouget; Yusuf A Rajabally; Teresa Sevilla; Ingemar S J Merkies
Journal:  J Peripher Nerv Syst       Date:  2018-12-11       Impact factor: 3.494

7.  Prevalence of, and factors associated with, long-term COVID-19 sick leave in working-age patients followed in general practices in Germany.

Authors:  Louis Jacob; Ai Koyanagi; Lee Smith; Christian Tanislav; Marcel Konrad; Susanne van der Beck; Karel Kostev
Journal:  Int J Infect Dis       Date:  2021-07-02       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.